How should tacrolimus (Prograf) be redosed in a patient with acute kidney injury (AKI)?

Tacrolimus Dosing in AKI: Continue with Therapeutic Drug Monitoring

In patients with acute kidney injury (AKI), tacrolimus should generally be continued with dose adjustments based on therapeutic drug monitoring (trough levels) rather than empirically stopped, as the drug is not renally eliminated and maintaining immunosuppression is critical to prevent rejection.

Key Principles for Tacrolimus Management in AKI

Pharmacokinetic Considerations

Tacrolimus is primarily metabolized hepatically via CYP3A enzymes, not renally eliminated. However, AKI significantly impacts tacrolimus pharmacokinetics through multiple mechanisms 1:

• Altered drug metabolism: AKI impairs hepatic cytochrome P450 activity and affects drug transporters, leading to unpredictable tacrolimus levels
• Changes in protein binding: Metabolic acidosis and uremia alter drug distribution
• Organ crosstalk: Kidney-liver interactions influence drug metabolism differently than in chronic kidney disease

The effects of AKI on drug metabolism cannot be extrapolated from CKD data due to different disease time courses 1.

Dosing Strategy in AKI

Monitor tacrolimus trough levels closely and adjust doses based on measured concentrations, not estimated renal function 2. The FDA label specifically addresses this:

• When serum creatinine is elevated with tacrolimus trough concentrations above the recommended range, consider dose reduction or temporary interruption 2
• The decision should be based on both the clinical context (severity of AKI, trend) and measured drug levels

Target Trough Levels

Maintain standard therapeutic ranges unless toxicity is evident 3:

• First month post-transplant: 6-10 ng/mL
• After first month: 4-8 ng/mL
• Long-term maintenance: Consider levels ≤4.5 ng/mL to minimize nephrotoxicity risk 4

Critical Monitoring Parameters

Increase monitoring frequency during AKI 2:

• Check trough levels every 1-3 days initially when AKI develops
• Monitor for neurotoxicity (tremors, mental status changes, seizures) as symptoms correlate with supratherapeutic levels 2
• Assess serum creatinine, potassium, and signs of tacrolimus toxicity

When to Reduce or Hold Tacrolimus

Consider dose reduction or temporary interruption when 1:

1. Tacrolimus is identified as the causal agent of AKI (drug-induced AKI)
2. Trough levels are consistently supratherapeutic (>15 ng/mL) with worsening renal function
3. Signs of tacrolimus toxicity appear (neurotoxicity, severe hyperkalemia)

Do NOT routinely discontinue tacrolimus solely because AKI is present - the risk of rejection typically outweighs nephrotoxicity concerns when levels are therapeutic 5.

Special Considerations

Concomitant Nephrotoxins

When AKI develops, review all medications 6, 7:

• Withdraw other nephrotoxic drugs (NSAIDs, aminoglycosides, amphotericin B) when possible
• Stop or reduce diuretics
• Avoid vasodilators that may worsen renal perfusion

The combination of tacrolimus with other nephrotoxins significantly increases AKI risk 2.

Drug Interactions During AKI

Be vigilant for CYP3A interactions that can rapidly alter tacrolimus levels 2:

• Strong CYP3A inhibitors (azole antifungals, protease inhibitors): Reduce tacrolimus to one-third of original dose and monitor levels within 1-3 days
• Strong CYP3A inducers (rifampin, phenytoin): Increase dose and monitor closely
• Changes in hepatic function during AKI may independently affect tacrolimus metabolism

Risk Factors for Tacrolimus-Induced Nephrotoxicity

Patients at higher risk for tacrolimus nephrotoxicity include 8, 9, 10:

• Male sex (4.4-fold increased risk)
• Pre-existing renal impairment (eGFR <43 mL/min/1.73m²)
• Supratherapeutic trough levels (>15 ng/mL)
• Prolonged exposure to high levels (cumulative area under curve)

In these patients, aim for the lower end of therapeutic ranges 4, 11.

Common Pitfalls to Avoid

1. Don't empirically stop tacrolimus when AKI develops - this risks acute rejection which has worse outcomes than managed nephrotoxicity
2. Don't dose adjust based on creatinine clearance formulas - tacrolimus is not renally eliminated; dose only by trough levels
3. Don't assume AKI is from tacrolimus - evaluate for prerenal causes, other nephrotoxins, and infection first 6, 7
4. Don't delay monitoring - supratherapeutic levels can develop rapidly, especially with new drug interactions 2

Algorithm for Management

When AKI develops in a patient on tacrolimus:

1. Immediately check tacrolimus trough level
2. Review medication list - remove other nephrotoxins, check for CYP3A interactions
3. Assess volume status - treat prerenal causes with albumin if indicated 6, 7
4. Based on trough level:
   • Therapeutic (within target range): Continue current dose, increase monitoring frequency to every 1-3 days
   • Supratherapeutic (>15 ng/mL): Reduce dose by 30-50% or hold 1-2 doses, recheck level in 24-48 hours
   • Subtherapeutic: Maintain or increase dose cautiously while addressing AKI causes
5. Monitor for toxicity: Neurotoxicity, hyperkalemia, worsening renal function
6. Reassess in 48-72 hours: Adjust based on trend in creatinine and tacrolimus levels

The goal is maintaining adequate immunosuppression while minimizing nephrotoxicity through precise therapeutic drug monitoring 3, 12.